Search results
Showing 1096 to 1110 of 1308 results for social care
Discontinued Reference number: GID-TA10166
Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]
Discontinued Reference number: GID-TA10892
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.
This guideline covers diagnosing and treating health-related fertility problems. It aims to reduce variation in practice and improve how fertility problems are investigated and managed.
Show all sections
Sections for NG257
- Overview
- Principles of care
- Initial advice to people concerned about delays in conception
- Advice about factors that can affect fertility
- Defining infertility and initial assessment
- Investigation of fertility problems and management strategies
- Management of male factor fertility problems
- Management of female factor fertility problems
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are ABL800 FLEX, i-STAT Alinity and StatSensor, ABL90 FLEX PLUS, Dri chem NX500, epoc Blood Analysis System, and Piccolo Xpress.
Discontinued Reference number: GID-TA10437
Discontinued Reference number: GID-TA10343
Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]
Discontinued Reference number: GID-TA10330
Discontinued Reference number: GID-TA10811
Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965]
Discontinued Reference number: GID-TA10870
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
In development Reference number: GID-TA10899 Expected publication date: TBC
Tanezumab for treating pain caused by bone metastases [ID3784]
Discontinued Reference number: GID-TA10922
In development Reference number: GID-TA11214 Expected publication date: TBC
Discontinued Reference number: GID-TA10668
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.